Molecular epidemiology and antifungal susceptibility of Serbian Cryptococcus neoformans isolates

Mycoses

Volumn 57, Issue 6, 2014, Pages 380-387

  Arsic Arsenijevic, Valentina ^a   Pekmezovic, Marina G ^a   Meis, Jacques F ^b,c   Hagen, Ferry ^b,c  

^a UNIVERSITY OF BELGRADE   (Serbia)

^b CANISIUS WILHELMINA HOSPITAL   (Netherlands)

^c RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Amplified fragment length polymorphism fingerprinting; Antifungal susceptibility; Cryptococcus neoformans; Molecular epidemiology; Serotyping

Indexed keywords

AMPHOTERICIN B; FLUCONAZOLE; FLUCYTOSINE; ITRACONAZOLE; POSACONAZOLE; VORICONAZOLE; ANTIFUNGAL AGENT;

AMPLIFIED FRAGMENT LENGTH POLYMORPHISM; ANTIFUNGAL SUSCEPTIBILITY; ARTICLE; BACTERIUM ISOLATE; CLINICAL ARTICLE; CRYPTOCOCCUS NEOFORMANS; FEMALE; GENOTYPE; HUMAN; HYBRID; IMMUNOCOMPROMISED PATIENT; IN VITRO STUDY; MALE; MATING; MOLECULAR EPIDEMIOLOGY; MOLECULAR TYPING; NONHUMAN; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; SEROTYPE; ANTIFUNGAL RESISTANCE; CLASSIFICATION; CRYPTOCOCCOSIS; DRUG EFFECTS; EPIDEMIOLOGY; ISOLATION AND PURIFICATION; MICROBIAL SENSITIVITY TEST; MICROBIOLOGICAL EXAMINATION; MICROBIOLOGY; PREVALENCE; RETROSPECTIVE STUDY; SERBIA;

FILOBASIDIELLA NEOFORMANS;

AMPLIFIED FRAGMENT LENGTH POLYMORPHISM ANALYSIS; ANTIFUNGAL AGENTS; CRYPTOCOCCOSIS; CRYPTOCOCCUS NEOFORMANS; DRUG RESISTANCE, FUNGAL; FEMALE; GENOTYPE; HUMANS; MALE; MICROBIAL SENSITIVITY TESTS; MOLECULAR EPIDEMIOLOGY; MOLECULAR TYPING; MYCOLOGICAL TYPING TECHNIQUES; PREVALENCE; RETROSPECTIVE STUDIES; SERBIA;

EID: 84900471144     PISSN: 09337407     EISSN: 14390507     Source Type: Journal    
DOI: 10.1111/myc.12171     Document Type: Article

References (38)

1. Warkentien T, Crum-Cianflone NF. An update on Cryptococcus among HIV-infected patients. Int J STD AIDS 2010; 21: 679-84.
2. Park BJ, Wannemuehler KA, Marston BJ, Govender N, Pappas PG, Chiller TM. Estimation of the current global burden of cryptococcal meningitis among persons living with HIV/AIDS. AIDS 2009; 23: 525-30.
3. Bovers M, Hagen F, Boekhout T. Diversity of the Cryptococcus neoformans-Cryptococcus gattii species complex. Rev Iberoam Micol 2008; 25: S4-S12.
4. Boekhout T, Theelen B, Diaz M et al. Hybrid genotypes in the pathogenic yeast Cryptococcus neoformans. Microbiology 2001; 147: 891-907.
5. Meyer W, Aanensen DM, Boekhout T et al. Consensus multi-locus sequence typing scheme for Cryptococcus neoformans and Cryptococcus gattii. Med Mycol 2009; 47: 561-70.
6. Hagen F, Illnait-Zaragozi MT, Bartlett KH et al. In vitro antifungal susceptibilities and amplified fragment length polymorphism genotyping of a worldwide collection of 350 clinical, veterinary, and environmental Cryptococcus gattii isolates. Antimicrob Agents Chemother 2010; 54: 5139-45.
7. Hagen F, Colom MF, Swinne D et al. Autochthonous and dormant Cryptococcus gattii infections in Europe. Emerg Infect Dis 2012a; 18: 1618-24.
8. Cogliati M. Global molecular epidemiology of Cryptococcus neoformans and Cryptococcus gattii: an atlas of the molecular types. Scientifica 2013; 2013: 675213.
9. Springer DJ, Chaturvedi V. Projecting global occurrence of Cryptococcus gattii. Emerg Infect Dis 2010; 16: 14-20.
10. Chowdhary A, Randhawa HS, Sundar G et al. In vitro antifungal susceptibility profiles and genotypes of 308 clinical and environmental isolates of Cryptococcus neoformans var. grubii and Cryptococcus gattii serotype B from north-western India. J Med Microbiol 2011; 60: 961-7.
11. Guinea J, Hagen F, Peláez T et al. Antifungal susceptibility, serotyping, and genotyping of clinical Cryptococcus neoformans isolates collected during 18 years in a single institution in Madrid, Spain. Med Mycol 2010; 48: 942-8.
12. Hagen F, Illnait-Zaragozí MT, Meis JF et al. Extensive genetic diversity within the Dutch clinical Cryptococcus neoformans population. J Clin Microbiol 2012b; 50: 1918-26.
13. Iqbal N, DeBess EE, Wohrle R et al.; Cryptococcus gattii Public Health Working Group. Correlation of genotype and in vitro susceptibilities of Cryptococcus gattii strains from the Pacific Northwest of the United States. J Clin Microbiol 2010; 48: 539-544.
14. Hagen F. Cryptococcus typing: what is in a name? Intern J Gerontol 2009; 3: 88.
15. Dromer F, Mathoulin S, Dupont B, Laporte A. Epidemiology of cryptococcosis in France: a 9-year survey (1985-1993). French Cryptococcosis Study Group. Clin Infect Dis 1996; 23: 82-90.
16. Mlinaric-Missoni E, Hagen F, Chew WH, Vazic-Babic V, Boekhout T, Begovac J. In vitro antifungal susceptibilities and molecular typing of sequentially isolated clinical Cryptococcus neoformans strains from Croatia. J Med Microbiol 2011; 60: 1487-95.
17. Tintelnot K, Lemmer K, Losert H, Schär G, Polak A. Follow-up of epidemiological data of cryptococcosis in Austria, Germany and Switzerland with special focus on the characterization of clinical isolates. Mycoses 2004; 47: 455-64.
18. Tintelnot K, Schär G, Polak A. Epidemiological data of cryptococcosis in Austria, Germany and Switzerland: part of the ECMM survey in Europe. European Confederation of Medical Mycology. Mycoses 2001; 44: 345-50.
19. Tortorano AM, Viviani MA, Rigoni AL, Cogliati M, Roverselli A, Pagano A. Prevalence of serotype D in Cryptococcus neoformans isolates from HIV positive and HIV negative patients in Italy. Mycoses 1997; 40: 297-302.
20. Trpković A, Pekmezović M, Barać A, Crnčević Radović L, Arsić Arsenijević V. In vitro antifungal activities of amphotericin B, 5-fluorocytosine, fluconazole and itraconazole against Cryptococcus neoformans isolated from cerebrospinal fluid and blood from patients in Serbia. J Mycol Méd 2012; 22: 243-8.
21. Viviani MA, Cogliati M, Esposto MC et al.; European Confederation of Medical Mycology (ECMM) Cryptococcosis Working Group. Molecular analysis of 311 Cryptococcus neoformans isolates from a 30-month ECMM survey of cryptococcosis in Europe. FEMS Yeast Res 2006; 6: 614-9.
22. Ren P, Roncaglia P, Springer DJ, Fan J, Chaturvedi V. Genomics organization and expression of 23 new genes from MATα locus of Cryptococcus neoformans var. gattii. Biochem Biophys Res Comm 2004; 326: 233-41.
23. Clinical and Laboratory Standards Institute. Reference method for broth dilution antifungal susceptibility testing of yeasts; Approved standard, 3rd edn, CLSI document M27-A3, Wayne, PA: Clinical and Laboratory Standards Institute, 2008.
24. Barreto de Oliveira MT, Boekhout T, Theelen B et al. Cryptococcus neoformans shows a remarkable genotypic diversity in Brazil. J Clin Microbiol 2004; 42: 1356-9.
25. Choi YH, Ngamskulrungroj P, Varma A et al. Prevalence of the VNIc genotype of Cryptococcus neoformans in non-HIV-associated cryptococcosis in the Republic of Korea. FEMS Yeast Res 2010; 10: 769-78.
26. Liaw SJ, Wu HC, Hsueh PR. Microbiological characteristics of clinical isolates of Cryptococcus neoformans in Taiwan: serotypes, mating types, molecular types, virulence factors, and antifungal susceptibility. Clin Microbiol Infect 2010; 16: 696-703.
27. Pan W, Khayhan K, Hagen F et al. Resistance of Asian Cryptococcus neoformans serotype A is confined to few microsatellite genotypes. PLoS ONE 2012; 7: e32868.
28. Illnait-Zaragozi MT, Martinez GF, Curfs-Breuker I, Fernandez CM, Boekhout T, Meis JF. In vitro activity of the new azole isavuconazole (BAL4815) compared with six other antifungal agents against 162 Cryptococcus neoformans isolates from Cuba. Antimicrob Agents Chemother 2008; 52: 1580-2.
29. Pfaller MA, Diekema DJ, Gibbs DL et al. Results from the ARTEMIS DISK Global Antifungal Surveillance Study, 1997 to 2007: 10.5-year analysis of susceptibilities of noncandidal yeast species to fluconazole and voriconazole determined by CLSI standardized disk diffusion testing. J Clin Microbiol 2009; 47: 117-23.
30. Pfaller MA, Messer SA, Boyken L et al. In vitro activities of voriconazole, posaconazole, and fluconazole against 4, 169 clinical isolates of Candida spp. and Cryptococcus neoformans collected during 2001 and 2002 in the ARTEMIS global antifungal surveillance program. Diagn Microbiol Infect Dis 2004; 48: 201-205.
31. Sabatelli F, Patel R, Mann PA et al. In vitro activities of posaconazole, fluconazole, itraconazole, voriconazole, and amphotericin B against a large collection of clinically important molds and yeasts. Antimicrob Agents Chemother 2006; 50: 2009-15.
32. Pfaller MA, Messer SA, Boyken L et al. Global trends in the antifungal susceptibility of Cryptococcus neoformans (1990 to 2004). J Clin Microbiol 2005; 43: 2163-7.
33. Datta K, Jain N, Sethi S, Rattan A, Casadevall A, Banerjee U. Fluconazole and itraconazole susceptibility of clinical isolates of Cryptococcus neoformans at a tertiary care centre in India: a need for care. J Antimicrob Chemother 2003; 52: 683-6.
34. Brandt ME, Pfaller MA, Hajjeh RA et al. Trends in antifungal drug susceptibility of Cryptococcus neoformans isolates in the United States: 1992 to 1994 and 1996 to 1998. Antimicrob Agents Chemother 2001; 45: 3065-9.
35. Perkins A, Gomez-Lopez A, Mellado E, Rodriguez-Tudela JL, Cuenca-Estrella M. Rates of antifungal resistance among Spanish clinical isolates of Cryptococcus neoformans var. neoformans. J Antimicrob Chemother 2005; 56: 1144-7.
36. Desnos-Ollivier M, Patel S, Spaulding AR et al. Mixed infections and in vivo evolution in the human fungal pathogen Cryptococcus neoformans. MBio 2010; 1: e00091-10.
37. Illnait-Zaragozí MT, Martínez-Machín GF, Fernández-Andreu CM et al. Microsatellite typing and susceptibilities of serial Cryptococcus neoformans isolates from Cuban patients with recurrent cryptococcal meningitis. BMC Infect Dis 2010; 10: 289.
38. Sullivan D, Haynes K, Moran G, Shanley D, Coleman D. Persistence, replacement, and microevolution of Cryptococcus neoformans strains in recurrent meningitis in AIDS patients. J Clin Microbiol 1996; 34: 1739-44.